The value of pharmaceuticals--some direction for employers

The costs of drugs keep rising. Are they worth it? Employers should consider value over cost, and make decisions based on diagnostics and research. They should thoroughly examine their organizations' experience to determine high-priority health conditions and do cost-effectiveness studies (usin...

Full description

Saved in:
Bibliographic Details
Published in:Employee Benefits Journal 2002-09, Vol.27 (3), p.31-35
Main Authors: Goetzel, Ron Z, Ozminkowski, Ronald J, Schutt, David C
Format: Magazinearticle
Language:English
Subjects:
Arthritis
Cardiovascular disease
Coronary vessels
Cost analysis
Cost control
Cost-Benefit Analysis
Decision Making
Disease - classification
Disease - economics
Drug Costs - trends
Drug prices
Drug Therapy
Employee benefits
Employer Health Costs - trends
Employers
Gastroesophageal reflux
Hay fever
Health administration
Health Benefit Plans, Employee - economics
Health Benefit Plans, Employee - organization & administration
Health care expenditures
Humans
Insurance, Pharmaceutical Services
Literature reviews
Mental disorders
Mental health
Nose
Pharmaceutical industry
Pharmaceuticals
Population
Productivity
Rhinitis
United States
Vein & artery diseases
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The costs of drugs keep rising. Are they worth it? Employers should consider value over cost, and make decisions based on diagnostics and research. They should thoroughly examine their organizations' experience to determine high-priority health conditions and do cost-effectiveness studies (using experienced consultants if necessary) that focus on all of the consequences of conditions and indicate the best medical and pharmaceutical therapies to treat them. Doing so should produce both human and financial dividends.
ISSN:0361-4050